nach oben

Inflammopharmacology

Erschienen in:

19.07.2021 | COVID-19 | Short Communication Zur Zeit gratis

COVID-19 vaccines and decreased transmission of SARS-CoV-2

verfasst von: A. Vitiello, F. Ferrara, V. Troiano, R. La Porta

Erschienen in: Inflammopharmacology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

A massive COVID-19 vaccination campaign is underway worldwide. Epidemiological data from studies indicate excellent efficacy and safety profile for COVID-19 vaccines. However, there are few data from studies on the effect of decreasing the probability of infection of vaccinated subjects compared to unvaccinated subjects. In this short communication, we describe some evidence on this important and current topic providing useful personal reflections.

Callaway E (2021) Delta coronavirus variant: scientists brace for impact. Nature 595(7865):17–18. https://doi.org/10.1038/d41586-021-01696-3 (PMID: 34158664)CrossRefPubMed

Ferrara F, Vitiello A (2021a) Scientific hypothesis for treatment of COVID-19’s lung lesions by adjusting ACE/ACE2 imbalance. Cardiovasc Toxicol. https://doi.org/10.1007/s12012-021-09649-y (Epub ahead of print. PMID: 33835386; PMCID: PMC8032553)CrossRefPubMedPubMedCentral

Ferrara F, Vitiello A (2021b) Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedeberg’s Arch Pharmacol. https://doi.org/10.1007/s00210-021-02049-7CrossRef

Ferrara F, Porta R, D’Aiuto V, Vitiello A (2020) Remdesivir and COVID-19. Ir J Med Sci. https://doi.org/10.1007/s11845-020-02401-5CrossRefPubMedPubMedCentral

Huff HV, Singh A (2020) Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies. Clin Infect Dis 71(10):2752–2756. https://doi.org/10.1093/cid/ciaa654 (PMID: 32463076; PMCID: PMC7314132)CrossRefPubMed

Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, Khan ST (2020) COVID-19: a global challenge with old history, epidemiology and progress so far. Molecules 26(1):39. https://doi.org/10.3390/molecules26010039 (PMID: 33374759; PMCID: PMC7795815)CrossRefPubMedCentral

Knoll MD, Wonodi C (2021) Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 397(10269):72–74. https://doi.org/10.1016/S0140-6736(20)32623-4 (Epub 2020 Dec 8. PMID: 33306990; PMCID: PMC7832220)CrossRefPubMed

Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, Balicer RD, Cramer JP, Muñoz-Fontela C, Gruber M, Gaspar R, Singh JA, Subbarao K, Van Kerkhove MD, Swaminathan S, Ryan MJ, Henao-Restrepo AM (2021) SARS-CoV-2 variants and vaccines. N Engl J Med. https://doi.org/10.1056/NEJMsr2105280

Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-Tov A, Kuint J, Gazit S, Patalon T, Chodick G, Kishony R (2021) Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med 27(5):790–792. https://doi.org/10.1038/s41591-021-01316-7 (Epub 2021 Mar 29. PMID: 33782619)CrossRefPubMed

Lurie N, Saville M, Hatchett R, Halton J (2020) Developing Covid-19 vaccines at pandemic speed. N Engl J Med 382(21):1969–1973. https://doi.org/10.1056/NEJMp2005630 (Epub 2020 Mar 30 PMID: 32227757)CrossRefPubMed

Petter E, Mor O, Zuckerman N, Oz-Levi D, Younger A, Aran D, Erlich Y (2021) Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. medRxiv. https://doi.org/10.1101/2021.02.08.21251329CrossRef

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577 (Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181)CrossRefPubMed

Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H (2021) Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 384(19):1824–1835. https://doi.org/10.1056/NEJMoa2034201CrossRefPubMed

Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski E, Edwards LJ, Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L, Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK, Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM, Gaglani M (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations December 2020–March 2021. MMWR Morb Mortal Wkly Rep 70(13):495–500. https://doi.org/10.15585/mmwr.mm7013e3 (PMID: 33793460; PMCID: PMC8022879)CrossRefPubMedPubMedCentral

Vitiello A, Ferrara F (2020) Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. https://doi.org/10.1007/s11845-020-02440-yCrossRefPubMedPubMedCentral

Vitiello A, Ferrara F (2021a) Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. Lung India 38(Supplement):S129–S130. https://doi.org/10.4103/lungindia.lungindia_803_20 (PMID: 33687000)CrossRefPubMedPubMedCentral

Vitiello A, Ferrara F (2021b) Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. Wien Klin Wochenschr. https://doi.org/10.1007/s00508-021-01855-6 (Epub ahead of print. PMID: 33877436)CrossRefPubMedPubMedCentral

Vitiello A, Ferrara F (2021c) Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. https://doi.org/10.1016/j.rmed.2021.106322CrossRefPubMedPubMedCentral

Vitiello A, Ferrara F, La Porta R (1971) Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. https://doi.org/10.1007/s11845-020-02482-2CrossRef

Vitiello A, Porta R, Pianesi L, Ferrara F (2021a) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. https://doi.org/10.1007/s11845-021-02584-5 (Epub ahead of print. PMID: 33710481)CrossRefPubMedPubMedCentral

Vitiello A, La Porta R, D’Aiuto V, Ferrara F (2021b) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. https://doi.org/10.1016/j.humimm.2021.01.007CrossRefPubMedPubMedCentral

Vitiello A, Pelliccia C, Ferrara F (2021c) Drugs acting on the renin–angiotensin system and SARS-CoV-2. Drug Discov Today. https://doi.org/10.1016/j.drudis.2021.01.010CrossRefPubMedPubMedCentral

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1 (PMID: 33306989; PMCID: PMC7723445)CrossRefPubMedPubMedCentral

Wang R, Chen J, Hozumi Y, Yin C, Wei GW (2020) Decoding asymptomatic COVID-19 infection and transmission. J Phys Chem Lett 11(23):10007–10015. https://doi.org/10.1021/acs.jpclett.0c02765 (PMID: 33179934; PMCID: PMC8150094)CrossRefPubMedPubMedCentral

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782–793. https://doi.org/10.1001/jama.2020.12839 (PMID: 32648899)CrossRefPubMed

Yu X, Yang R (2020) COVID19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses 14(4):474–475. https://doi.org/10.1111/irv.12743 (Epub 2020 Apr 15. PMID: 32246886; PMCID: PMC7228388)CrossRefPubMedPubMedCentral

Titel: COVID-19 vaccines and decreased transmission of SARS-CoV-2
verfasst von: A. Vitiello
F. Ferrara
V. Troiano
R. La Porta
Publikationsdatum: 19.07.2021
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Inflammopharmacology / Ausgabe 5/2021
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-021-00847-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug

Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer’s disease: flavonoids and phenols

Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial

Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases

Fatty ethanolamide of Bertholletia excelsa triglycerides (Brazil nuts): anti-inflammatory action and acute toxicity evaluation in Zebrafish (Danio rerio)

Anti-inflammatory and antioxidant properties of Alternanthera brasiliana improve cutaneous wound healing in rats